Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance

European Journal of Pharmaceutical Sciences

Volumn 94, Issue , 2016, Pages 59-71

  Scotcher, Daniel ^a   Jones, Christopher ^b   Rostami Hodjegan, Amin ^a,c   Galetin, Aleksandra ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c CERTARA UK LIMITED   (United Kingdom)

Author keywords

In vitro in vivo extrapolation; Renal excretion clearance; Tubular reabsorption

Indexed keywords

APRINDINE; ATENOLOL; BETAMETHASONE; BETAXOLOL; CAFFEINE; CHLORPHENIRAMINE; CHLORPROPAMIDE; CITALOPRAM; DAPSONE; DIFLOXACIN; DOXEPIN; FLUCONAZOLE; GABAPENTIN; GREPAFLOXACIN; IMIPRAMINE; IRBESARTAN; ISOXICAM; LEVETIRACETAM; LINEZOLID; MELAGATRAN; METOPROLOL; METRONIDAZOLE; MEXILETINE; MOCLOBEMIDE; MOXIFLOXACIN; OXPRENOLOL; OXYTETRACYCLINE; PEFLOXACIN; PHENAZONE; UNINDEXED DRUG; DRUG;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; CACO 2 CELL LINE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; FLOW RATE; HUMAN; IN VITRO IN VIVO EXTRAPOLATION; KIDNEY TUBULE ABSORPTION; NORMAL HUMAN; PH; PREDICTION; PRIORITY JOURNAL; RENAL CLEARANCE; RENAL EXCRETION CLEARANCE; SURFACE AREA; VALIDATION STUDY; BIOLOGICAL MODEL; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; GLOMERULUS FILTRATION RATE; KIDNEY TUBULE; METABOLIC CLEARANCE RATE; METABOLISM; PHYSIOLOGY; PROCEDURES; URINARY EXCRETION;

CLINICAL TRIALS AS TOPIC; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY TUBULES; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; RENAL ELIMINATION;

EID: 84962683084     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2016.03.018     Document Type: Article

References (74)

1. Artursson, P., Palm, K., Luthman, K., Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev., 46, 2001, 27, 10.1016/S0169-409X(00)00128-9.
2. Avdeef, A., Tam, K.Y., How well can the Caco-2/Madin–Darby canine kidney models predict effective human jejunal permeability?. J. Med. Chem., 53(9), 2010, 3566, 10.1021/jm901846t.
3. Bentz, J., O'Connor, M.P., Bednarczyk, D., Coleman, J., Lee, C., Palm, J., Pak, Y.A., Perloff, E.S., Reyner, E., Balimane, P., Variability in P-glycoprotein inhibitory potency (IC50) using various in vitro experimental systems: implications for universal digoxin drug–drug interaction risk assessment decision criteria. Drug Metab. Dispos., 41(7), 2013, 1347, 10.1124/dmd.112.050500.
4. Birkett, D., Miners, J., Caffeine renal clearance and urine caffeine concentrations during steady state dosing. Implications for monitoring caffeine intake during sports events. Br. J. Clin. Pharmacol., 31(4), 1991, 405, 10.1111/j.1365-2125.1991.tb05553.x.
5. Brown, C., Sayer, R., Windass, A., Haslam, I., De Broe, M., D'Haese, P., Verhulst, A., Characterisation of human tubular cell monolayers as a model of proximal tubular xenobiotic handling. Toxicol. Appl. Pharmacol., 233(3), 2008, 428, 10.1016/j.taap.2008.09.018.
6. Chew-Harris, J.S., Chin, P.K., Florkowski, C.M., George, P., Endre, Z., Removal of body surface area normalisation improves raw-measured GFR estimation by the CKD-EPI equation and drug dosing in the obese. Intern. Med. J., 45(7), 2015, 466, 10.1111/imj.12791.
7. Darmady, E., Offer, J., Woodhouse, M., The parameters of the ageing kidney. J. Pathol., 109(3), 1973, 195, 10.1002/path.1711090304.
8. Dave, R., Morris, M., Quantitative structure–pharmacokinetic relationships for the prediction of renal clearance in humans. Drug Metab. Dispos., 43(1), 2015, 73, 10.1124/dmd.114.059857.
9. Dave, R.A., Morris, M.E., Semi-mechanistic kidney model incorporating physiologically-relevant fluid reabsorption and transporter-mediated renal reabsorption: pharmacokinetics of γ-hydroxybutyric acid and l-lactate in rats. J. Pharmacokinet. Pharmacodyn., 42(5), 2015, 497, 10.1007/s10928-015-9441-1.
10. Delanaye, P., Schaeffner, E., Ebert, N., Cavalier, E., Mariat, C., Krzesinski, J., Moranne, O., Normal reference values for glomerular filtration rate: what do we really know?. Nephrol. Dial. Transplant., 27(7), 2012, 2664, 10.1093/ndt/gfs265.
11. Dooley, M.J., Poole, S.G., Poor correlation between body surface area and glomerular filtration rate. Cancer Chemother. Pharmacol., 46(6), 2000, 523, 10.1007/PL00006751.
12. Felmlee, M.A., Dave, R.A., Morris, M.E., Mechanistic models describing active renal reabsorption and secretion: a simulation-based study. AAPS J., 15(1), 2013, 278, 10.1208/s12248-012-9437-3.
13. Fetterman, G., Shuplock, N., Philipp, F., Gregg, H., The growth and maturation of human glomeruli and proximal convolutions from term to adulthood: studies by microdissection. Pediatrics, 35, 1965, 601.
14. Fouda, A., Fauth, C., Roch-Ramel, F., Transport of organic cations by kidney epithelial cell line LLC-PK1. J. Pharmacol. Exp. Ther., 252(1), 1990, 286.
15. Galetin, A., Rationalizing underprediction of drug clearance from enzyme and transporter kinetic data: from in vitro tools to mechanistic modeling. Nagar, S., Argikar, A.U., Tweedie, J.D., (eds.) Enzyme Kinetics in Drug Metabolism: Fundamentals and Applications, 2014, Humana Press, Totowa, NJ, 255.
16. Gertz, M., Harrison, A., Houston, J.B., Galetin, A., Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab. Dispos., 38(7), 2010, 1147, 10.1124/dmd.110.032649.
17. Giacomini, K.M., Huang, S.-M., Tweedie, D.J., Benet, L.Z., Brouwer, K.L., Chu, X., Dahlin, A., Evers, R., Fischer, V., Hillgren, K.M., Membrane transporters in drug development. Nat. Rev. Drug Discov., 9(3), 2010, 215, 10.1038/nrd3028.
18. Gill, K.L., Houston, J.B., Galetin, A., Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin. Drug Metab. Dispos., 40(4), 2012, 825, 10.1124/dmd.111.043984.
19. Gill, K.L., Gertz, M., Houston, J.B., Galetin, A., Application of a physiologically based pharmacokinetic model to assess propofol hepatic and renal glucuronidation in isolation: utility of in vitro and in vivo data. Drug Metab. Dispos., 41(4), 2013, 744, 10.1124/dmd.112.050294.
20. Hall, S., Rowland, M., Relationship between renal clearance, protein binding and urine flow for digitoxin, a compound of low clearance in the isolated perfused rat kidney. J. Pharmacol. Exp. Ther., 228(1), 1984, 174.
21. Hasegawa, M., Kusuhara, H., Endou, H., Sugiyama, Y., Contribution of organic anion transporters to the renal uptake of anionic compounds and nucleoside derivatives in rat. J. Pharmacol. Exp. Ther., 305(3), 2003, 1087, 10.1124/jpet.102.046847.
22. Higgins, J., Thompson, S.G., Quantifying heterogeneity in a meta-analysis. Stat. Med., 21(11), 2002, 1539, 10.1002/sim.1186.
23. Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ, 327(7414), 2003, 557, 10.1136/bmj.327.7414.557.
24. Hsu, V., de LT Vieira, M., Zhao, P., Zhang, L., Zheng, J.H., Nordmark, A., Berglund, E.G., Giacomini, K.M., Huang, S.-M., Towards quantitation of the effects of renal impairment and probenecid Inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations. Clin. Pharmacokinet., 53(3), 2014, 283, 10.1007/s40262-013-0117-y.
25. Huffman, D., Shoeman, D., Azarnoff, D., Correlation of the plasma elimination of antipyrine and the appearance of 4-hydroxy antipyrine in the urine of man. Biochem. Pharmacol., 23(2), 1974, 197, 10.1016/0006-2952(74)90410-9.
26. Huh, Y., Smith, D.E., Rose Feng, M., Interspecies scaling and prediction of human clearance: comparison of small-and macro-molecule drugs. Xenobiotica, 41(11), 2011, 972, 10.3109/00498254.2011.598582.
27. Irvine, J.D., Takahashi, L., Lockhart, K., Cheong, J., Tolan, J.W., Selick, H., Grove, J.R., MDCK (Madin–Darby canine kidney) cells: a tool for membrane permeability screening. J. Pharm. Sci., 88(1), 1999, 28, 10.1021/js9803205.
28. Ito, S., Ando, H., Ose, A., Kitamura, Y., Ando, T., Kusuhara, H., Sugiyama, Y., Relationship between the urinary excretion mechanisms of drugs and their physicochemical properties. J. Pharm. Sci., 102(9), 2013, 3294, 10.1002/jps.23599.
29. Jadhav, P.R., Cook, J., Sinha, V., Zhao, P., Rostami-Hodjegan, A., Sahasrabudhe, V., Stockbridge, N., Powell, J.R., A proposal for scientific framework enabling specific population drug dosing recommendations. J. Clin. Pharmacol., 55(10), 2015, 1073, 10.1002/jcph.579.
30. Jones, G.R., Estimating renal function for drug dosing decisions. Clin. Biochem. Rev., 32(2), 2011, 81.
31. Kah, M., Brown, C.D., LogD: lipophilicity for ionisable compounds. Chemosphere, 72(10), 2008, 1401, 10.1016/j.chemosphere.2008.04.074.
32. Knights, K.M., Spencer, S.M., Fallon, J.K., Chau, N., Smith, P.C., Miners, J.O., Scaling factors for the in vitro-in vivo extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearance. Br. J. Clin. Pharmacol., 2016, 10.1111/bcp.12889.
33. Kunze, A., Huwyler, J., Poller, B., Gutmann, H., Camenisch, G., In vitro-in vivo extrapolation method to predict human renal clearance of drugs. J. Pharm. Sci., 103(3), 2014, 994, 10.1002/jps.23851.
34. Layton, A.T., A mathematical model of the urine concentrating mechanism in the rat renal medulla. I. Formulation and base-case results. Am. J. Physiol. Ren. Physiol., 300(2), 2011, F356, 10.1152/ajprenal.00203.2010.
35. Mawer, G., Lee, H., Value of forced diuresis in acute barbiturate poisoning. BMJ, 2(5608), 1968, 790, 10.1136/bmj.2.5608.790.
36. Moestrup, S.K., Cui, S., Vorum, H., Bregengård, C., Bjørn, S., Norris, K., Gliemann, J., Christensen, E.I., Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. J. Clin. Invest., 96(3), 1995, 1404, 10.1172/JCI118176.
37. Morrissey, K., Wen, C., Johns, S., Zhang, L., Huang, S., Giacomini, K., The UCSF-FDA TransPortal: a public drug transporter database. Clin. Pharmacol. Ther., 92(5), 2012, 545, 10.1038/clpt.2012.44.
38. Morrissey, K., Stocker, S., Wittwer, M., Xu, L., Giacomini, K., Renal transporters in drug development. Annu. Rev. Pharmacol. Toxicol., 53, 2013, 503, 10.1146/annurev-pharmtox-011112-140317.
39. Nagai, J., Takano, M., Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metab. Pharmacokinet., 19(3), 2004, 159, 10.2133/dmpk.19.159.
40. Neuhoff, S., Gaohua, L., Burt, H., Jamei, M., Li, L., Tucker, G.T., Rostami-Hodjegan, A., Accounting for transporters in renal clearance: towards a mechanistic kidney model (Mech KiM). Sugiyama, Y., Steffansen, B., (eds.) Transporters in Drug Development, 2013, Springer, 155.
41. Nyman, H., Dowling, T., Hudson, J., Peter, W., Joy, M., Nolin, T., Comparative evaluation of the Cockcroft–Gault equation and the Modification of Diet in Renal Disease (MDRD) study equation for drug dosing: an opinion of the Nephrology Practice and Research Network of the American College of Clinical Pharmacy. Pharmacotherapy, 31(11), 2011, 1130, 10.1592/phco.31.11.1130.
42. Olivares-Morales, A., Lennernäs, H., Aarons, L., Rostami-Hodjegan, A., Translating human effective jejunal intestinal permeability to surface-dependent intrinsic permeability: a pragmatic method for a more mechanistic prediction of regional oral drug absorption. AAPS J., 17(5), 2015, 1177, 10.1208/s12248-015-9758-0.
43. Ozawa, N., Shimizu, T., Morita, R., Yokono, Y., Ochiai, T., Munesada, K., Ohashi, A., Aida, Y., Hama, Y., Taki, K., Transporter database, TP-search: a web-accessible comprehensive database for research in pharmacokinetics of drugs. Pharm. Res., 21(11), 2004, 2133, 10.1023/B:PHAM.0000048207.11160.d0.
44. Özdemir, M., Crewe, K.H., Tucker, G.T., Rostami-Hodjegan, A., Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH. J. Clin. Pharmacol., 44(12), 2004, 1398, 10.1177/0091270004269582.
45. Pai, M.P., Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv. Chronic Kidney Dis., 17(5), 2010, e53, 10.1053/j.ackd.2010.05.010.
46. Paine, S., Barton, P., Bird, J., Denton, R., Menochet, K., Smith, A., Tomkinson, N., Chohan, K., A rapid computational filter for predicting the rate of human renal clearance. J. Mol. Graphics Modell., 29(4), 2010, 529, 10.1016/j.jmgm.2010.10.003.
47. Paine, S., Ménochet, K., Denton, R., McGinnity, D., Riley, R., Prediction of human renal clearance from preclinical species for a diverse set of drugs that exhibit both active secretion and net reabsorption. Drug Metab. Dispos., 39(6), 2011, 1008, 10.1124/dmd.110.037267.
48. Posada, M., Bacon, J., Schneck, K., Tirona, R., Kim, R., Higgins, J., Pak, Y., Hall, S., Hillgren, K., Prediction of renal transporter mediated drug–drug interactions for pemetrexed using physiologically based pharmacokinetic modeling. Drug Metab. Dispos., 43(3), 2015, 325, 10.1124/dmd.114.059618.
49. Rostami-Hodjegan, A., Complex patients-complex DDI: is there a straight way forward?. Biopharm. Drug Dispos., 36(2), 2015, 69, 10.1002/bdd.1939.
50. Schmitz, C., Hilpert, J., Jacobsen, C., Boensch, C., Christensen, E., Luft, F., Willnow, T., Megalin deficiency offers protection from renal aminoglycoside accumulation. J. Biol. Chem., 277(1), 2002, 618, 10.1074/jbc.M109959200.
51. Shaw, P., Houston, J., Rowland, M., Hopkins, K., Thiercelin, J., Morselli, P., Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamazepine. Br. J. Clin. Pharmacol., 20(6), 1985, 611, 10.1111/j.1365-2125.1985.tb05119.x.
52. Simerville, J., Maxted, W., Pahira, J., Urinalysis: a comprehensive review. Am. Fam. Physician, 71(6), 2005, 1153.
53. Smith, D., Artursson, P., Avdeef, A., Di, L., Ecker, G.F., Faller, B., Houston, J.B., Kansy, M., Kerns, E.H., Krämer, S.D., Passive lipoidal diffusion and carrier-mediated cell uptake are both important mechanisms of membrane permeation in drug disposition. Mol. Pharm., 11(6), 2014, 1727, 10.1021/mp400713v.
54. Sohlenius-Sternbeck, A.-K., Jones, C., Ferguson, D., Middleton, B.J., Projean, D., Floby, E., Bylund, J., Afzelius, L., Practical use of the regression offset approach for the prediction of in vivo intrinsic clearance from hepatocytes. Xenobiotica, 42(9), 2012, 841, 10.3109/00498254.2012.669080.
55. Soveri, I., Berg, U., Björk, J., Elinder, C., Grubb, A., Mejare, I., Sterner, G., Bäck, S., SBU, G., Measuring GFR: a systematic review. Am. J. Kidney Dis., 64(3), 2014, 411, 10.1053/j.ajkd.2014.04.010.
56. Sterner, G., Frennby, B., Mansson, S., Nyman, U., Van Westen, D., Almén, T., Determining ‘true’ glomerular filtration rate in healthy adults using infusion of inulin and comparing it with values obtained using other clearance techniques or prediction equations. Scand. J. Urol. Nephrol., 42(3), 2008, 278, 10.1080/00365590701701806.
57. Strolin, B.M., Whomsley, R., Mathy, F., Jacques, P., Espie, P., Canning, M., Stereoselective renal tubular secretion of levocetirizine and dextrocetirizine, the two enantiomers of the H1-antihistamine cetirizine. Fundam. Clin. Pharmacol., 22(1), 2008, 19, 10.1111/j.1472-8206.2007.00543.x.
58. Tang-Liu, D., Williams, R., Riegelman, S., Nonlinear theophylline elimination. Clin. Pharmacol. Ther., 31(3), 1982, 358, 10.1038/clpt.1982.46.
59. Tang-Liu, D., Tozer, T., Riegelman, S., Dependence of renal clearance on urine flow: a mathematical model and its application. J. Pharm. Sci., 72(2), 1983, 154, 10.1002/jps.2600720215.
60. (+)-organic cation antiporters. Biochem. Pharmacol., 74(2), 2007, 359, 10.1016/j.bcp.2007.04.010.
61. Taylor, G., Blaschke, T., Measurement of antipyrine half-life from urinary drug concentrations [letter]. Br. J. Clin. Pharmacol., 18(4), 1984, 650, 10.1111/j.1365-2125.1984.tb02524.x.
62. Trifillis, A., Kahng, M., Characterization of an in vitro system of human renal papillary collecting duct cells. In Vitro Cell. Dev. Biol., 26(5), 1990, 441, 10.1007/BF02624085.
63. Tucker, G., Measurement of the renal clearance of drugs. Br. J. Clin. Pharmacol., 12(6), 1981, 761, 10.1111/j.1365-2125.1981.tb01304.x.
64. Urakami, Y., Kimura, N., Okuda, M., Inui, K., Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm. Res., 21(6), 2004, 976, 10.1023/B:PHAM.0000029286.45788.ad.
65. Varma, M., Feng, B., Obach, R., Troutman, M., Chupka, J., Miller, H., El-Kattan, A., Physicochemical determinants of human renal clearance. J. Med. Chem., 52(15), 2009, 4844, 10.1021/jm900403j.
66. Varma, M.V., Steyn, S.J., Allerton, C., El-Kattan, A.F., Predicting clearance mechanism in drug discovery: Extended Clearance Classification System (ECCS). Pharm. Res., 32(12), 2015, 3785, 10.1007/s11095-015-1749-4.
67. Vree, T.B., van Ewijk-Beneken Kolmer, E.W.J., Wuis, E.W., Hekster, Y.A., Broekman, M.M.M., Interindividual variation in the capacity-limited renal glucuronidation of probenecid by humans. Pharm. World Sci., 15(5), 1993, 197.
68. Watanabe, T., Kusuhara, H., Watanabe, T., Debori, Y., Maeda, K., Kondo, T., Nakayama, H., Horita, S., Ogilvie, B., Parkinson, A., Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug–drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab. Dispos., 39(6), 2011, 1031, 10.1124/dmd.110.036129.
69. Weinstein, A.M., A mathematical model of rat proximal tubule and loop of Henle. Am. J. Physiol. Ren. Physiol., 308(10), 2015, F1076, 10.1152/ajprenal.00504.2014.
70. Welling, L., Welling, D., Relationship between structure and function in renal proximal tubule. J. Electron Microsc. Tech., 9(2), 1988, 171, 10.1002/jemt.1060090205.
71. Welling, L., Evan, A., Welling, D., Shape of cells and extracellular channels in rabbit cortical collecting ducts. Kidney Int., 20(2), 1981, 211, 10.1038/ki.1981.123.
72. Wenlock, M.C., Potter, T., Barton, P., Austin, R.P., A method for measuring the lipophilicity of compounds in mixtures of 10. J. Biomol. Screen., 16(3), 2011, 348, 10.1177/1087057110396372.
73. Zamek-Gliszczynski, M.J., Lee, C.A., Poirier, A., Bentz, J., Chu, X., Ellens, H., Ishikawa, T., Jamei, M., Kalvass, J.C., Nagar, S., ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans. Clin. Pharmacol. Ther., 94(1), 2013, 64, 10.1038/clpt.2013.45.
74. Zhao, P., Zhang, L., Grillo, J., Liu, Q., Bullock, J., Moon, Y., Song, P., Brar, S., Madabushi, R., Wu, T., Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin. Pharmacol. Ther., 89(2), 2011, 259, 10.1038/clpt.2010.298.